AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...

TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at ...

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

BRITISH pharmaceutical giant AstraZeneca said on Friday (Jan 31) that it was abandoning plans to build a £450 million (S$756.9 million) vaccine plant, a major blow to the Labour government’s plans to ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...